Matinas BioPharma Holdings (MTNB) Change in Accured Expenses (2013 - 2026)
Matinas BioPharma Holdings (MTNB) reported Change in Accured Expenses of $242000.0 for Q1 2026, up 138.6% year-over-year from $101426.5 in Q1 2025, and up 310.43% quarter-over-quarter from -$115000.0 in Q4 2025.
Matinas BioPharma Holdings (MTNB) Change in Accured Expenses (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 14 years of Change in Accured Expenses data on file, last reported at $242000.0 in Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at $242000.0, up 138.6% year-over-year; the trailing twelve-month figure through Mar 2026 was -$484000.0 (down 242.77% YoY), and the FY2025 annual result was -$1.4 million, down 480.06% from the prior year.
- Change in Accured Expenses rose to $242000.0 in Q1 2026 per MTNB's latest filing, from -$115000.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $2.5 million in Q2 2022 and troughed at -$2.3 million in Q1 2023.
- A 5-year average of -$126882.4 and a median of -$311000.0 in 2023 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses slumped 1335.99% in 2022, then soared 346.3% in 2024.
- A 5-year view of Change in Accured Expenses shows it stood at -$597000.0 in 2022, then soared by 47.91% to -$311000.0 in 2023, then soared by 346.3% to $766000.0 in 2024, then tumbled by 115.01% to -$115000.0 in 2025, then surged by 310.43% to $242000.0 in 2026.
- Business Quant data shows MTNB's Change in Accured Expenses at $242000.0 in Q1 2026, -$115000.0 in Q4 2025, and -$230000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 931,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - | 242,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 242,000.00 |
| Mar 31, 2026 | 242,000.00 |
| Dec 31, 2025 | -115,000.00 |
| Dec 31, 2025 | -115,000.00 |
| Sep 30, 2025 | -230,000.00 |
| Sep 30, 2025 | -230,000.00 |
| Jun 30, 2025 | -381,000.00 |
| Jun 30, 2025 | -381,000.00 |
| Mar 31, 2025 | -627,000.00 |
| Mar 31, 2025 | -627,000.00 |
| Dec 31, 2024 | 766,000.00 |
| Dec 31, 2024 | 766,000.00 |
| Sep 30, 2024 | -404,000.00 |
| Sep 30, 2024 | -404,000.00 |
| Jun 30, 2024 | 604,000.00 |
| Jun 30, 2024 | 604,000.00 |
| Mar 31, 2024 | -610,000.00 |
| Mar 31, 2024 | -610,000.00 |
| Dec 31, 2023 | -311,000.00 |
| Dec 31, 2023 | -311,000.00 |